Achillion is a pharmaceutical company developing treatments for patients with challenging infectious diseases – hepatitis C and resistant bacterial infections.
With three distinct, proprietary programs for hepatitis C infection, Achillion is seeking to capitalize on an important unmet medical need: the emergence of drug resistance to current antiviral and antibacterial therapies, which creates a continuing need for new drugs. The hepatitis C virus is the most common cause of viral hepatitis, with over 170 million victims worldwide and 5 million in the United States.
New Haven, CT
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.